<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01338675</url>
  </required_header>
  <id_info>
    <org_study_id>SNUCH-SCT -1002</org_study_id>
    <nct_id>NCT01338675</nct_id>
  </id_info>
  <brief_title>Targeted Busulfan, Fludarabine Conditioning Regimen for Hematopoietic Stem Cell Transplantation in Chronic Granulomatous Disease(CGD)</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Seoul National University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Seoul National University Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      In this study the investigators plan to use optimal busulfan dose through pharmacokinetic
      study in stem cell transplantation of CGD patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Chronic granulomatous disease is one of the rare congenital immunodeficiency which can be
      cured by hematopoietic stem cell transplantation. Previous myeloablative conditioning regimen
      has problems related to the severe toxicities, and non-myeloablative conditioning regimen has
      the risk of graft failure. Recently, reduced-intensity myeloablative conditioning regimen
      with busulfan and fludarabine was used usually in leukemia patients.

      Busulfan is a highly toxic drug with narrow therapeutic window. In this study we plan to use
      optimal busulfan dose through pharmacokinetic study in stem cell transplantation of CGD
      patients.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>January 2011</start_date>
  <completion_date type="Anticipated">December 2013</completion_date>
  <primary_completion_date type="Anticipated">December 2013</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Engraftment rate</measure>
    <time_frame>1 month after transplantation</time_frame>
    <description>To evaluate engraftment rate after hematopoietic stem cell transplantation.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Transplantation-related mortality and toxicities</measure>
    <time_frame>1, 3, 6 and 12 months after transplantation</time_frame>
    <description>To evaluate 1-year event free survival after hematopoietic stem cell transplantation, toxicities associated with hematopoietic stem cell transplantation, acute and chronic GVHD, treatment related mortality and relapse rate.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">5</enrollment>
  <condition>Chronic Granulomatous Disease</condition>
  <arm_group>
    <arm_group_label>Busulfan</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>First dose: busulfan (120 mg/m2 ivs once daily) (if age&lt;1 yr: 80 mg/ m2) Second to forth dose: according to the daily pharmacokinetic study</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Busulfan</intervention_name>
    <description>First dose: busulfan (120 mg/m2 ivs once daily) (if age&lt;1 yr: 80 mg/ m2) Second to forth dose: according to the daily pharmacokinetic study</description>
    <arm_group_label>Busulfan</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients who are diagnosed as CGD.

          -  Patients who need hematopoietic stem cell transplantation with busulfan based
             conditioning regimen.

          -  Age: No limit.

          -  Performance status: ECOG 0-2.

          -  Patients must be free of significant functional deficits in major organs, but the
             following eligibility criteria may be modified in individual cases.

          -  Heart: a shortening fraction &gt; 30% and ejection fraction &gt; 45%.

          -  Liver: total bilirubin &lt; 2 × upper limit of normal; ALT &lt; 3 × upper limit of normal.

          -  Kidney: creatinine &lt;2 × normal or a creatinine clearance (GFR) &gt; 60 ml/min/1.73m2.

          -  Patients must lack any active viral infections or active fungal infection.

          -  Appropriate donor is available.

          -  Patients (or one of parents if patients age &lt; 20) should sign informed consent.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hyoung Jin Kang, M.D., Ph.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Seoul National University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Hyoung Jin Kang, MD, PhD</last_name>
    <phone>82 2 2072 3304</phone>
    <email>kanghj@snu.ac.kr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Ji Won Lee, MD</last_name>
    <phone>82 2 2072 0177</phone>
    <email>agnesjw@hanmail.net</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Seoul National University Hospital</name>
      <address>
        <city>Seoul</city>
        <state>Daehangno, Jongno-gu</state>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hyoung Jin Kang, MD, PhD</last_name>
      <phone>82 2 2072 3304</phone>
      <email>kanghj@snu.ac.kr</email>
    </contact>
    <contact_backup>
      <last_name>Ji Won Lee, MD</last_name>
      <phone>82 2 2072 0177</phone>
      <email>agnesjw@hanmail.net</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>November 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 4, 2011</study_first_submitted>
  <study_first_submitted_qc>April 18, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 19, 2011</study_first_posted>
  <last_update_submitted>November 17, 2013</last_update_submitted>
  <last_update_submitted_qc>November 17, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 19, 2013</last_update_posted>
  <keyword>Chronic granulomatous disease</keyword>
  <keyword>Hematopoietic Stem Cell Transplantation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Granuloma</mesh_term>
    <mesh_term>Granulomatous Disease, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Busulfan</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

